CJC-1295 with DAC and Semaglutide Interaction

Monitor
Mechanism-based 47% confidence

CJC-1295 with DAC and Semaglutide have an interaction requiring monitoring for interaction with 47% confidence. Both CJC-1295 with DAC and Semaglutide affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). Both compounds affect the gi tract, so monitoring these systems is recommended.

Compound Profiles

CJC-1295 with DAC

Long-Acting Growth Hormone Releasing Hormone Analog | Extended Release

DAC binds to albumin, extending half-life to 6-8 days and providing continuous GHRH receptor stimulation for sustained GH/IGF-1 elevation..

Half-life: 6-8 days Typical dose: 1-2mg weekly growth hormone, weight loss
ghrh receptorigf1 carcinogenic riskestrogenicinsulin disrupting
View full profile

Semaglutide

GLP-1 Receptor Agonist | Weight Loss & Diabetes

Mimics native GLP-1, binding to receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite via hypothalamic pathways..

Half-life: ~7 days (168 hours) Typical dose: 0.25mg starting, titrate to 1-2.4mg weekly weight loss, metabolic
glp1 receptor carcinogenic riskinsulin disruptingteratogenic
View full profile

Combined Organ Load

GI Tract
low
Pituitary
low
Pancreas
low

Shared Safety Flags

2x 2 compounds share the carcinogenic-risk safety flag (CJC-1295 with DAC, Semaglutide). Monitor accordingly.
2x 2 compounds affect insulin sensitivity (CJC-1295 with DAC, Semaglutide). Monitor fasting glucose and HbA1c.

Frequently Asked Questions

Can I take CJC-1295 with DAC with Semaglutide?

Yes, but with caution. Both CJC-1295 with DAC and Semaglutide affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). Regular monitoring is advised.

Is CJC-1295 with DAC and Semaglutide safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: carcinogenic risk, insulin disrupting. Monitor accordingly.

What are the interactions between CJC-1295 with DAC and Semaglutide?

Both CJC-1295 with DAC and Semaglutide affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). This assessment has 47% confidence and is inferred from pharmacological mechanism analysis.

How should I time CJC-1295 with DAC and Semaglutide?

CJC-1295 with DAC has a half-life of 6-8 days and Semaglutide has a half-life of ~7 days (168 hours). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: CJC-1295 with DAC vs Semaglutide

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.